Back to top

Image: Bigstock

Top Research Reports for Today: BMY, RDS.A, FB

Read MoreHide Full Article

Wednesday, December 14 2016

Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers (BMY - Free Report) , Shell and Facebook .

Buy-rated Bristol-Myers shares have underperformed the broader market as well as the large cap pharma group this year, though the stock has turned around a bit since the election. Concerns about generic competition for several of its key products, particularly the HCV franchise, remain a major headwind for the stock. These issues notwithstanding, the analyst points out in the updated research report issued today Bristol-Myers’ efforts to develop its pipeline and strengthen its product portfolio, primarily through acquisitions and deals. An operating model focused on accelerating pipeline development and streamlining infrastructure bodes well for growth. (You can read the full research report on Bristol-Myers here.)

Shares of Buy-rated Shell have increased 18% year-to-date, marginally higher than the broader oil and gas integrated sector. Moreover, Europe's largest oil company reported better-than-expected earnings during the third quarter despite the difficult operating environment. The Zacks analyst likes the company’s expense management and progress on its large divestment program. Shell's near-term dividend outlook also looks good with the company delivering on its pledge to sustain the payout throughout 2016. Moreover, with the latest decision of both OPEC and non-OPEC players to cut oil production amid the supply glut, crude price has somewhat recovered. (You can read the full research report on Shell here.)

Facebook shares have vastly outperformed the Internet services industry year-to-date, gaining more than 13% over the period. However the stock has lagged following the company's quarterly report when it came out with blowout numbers for the September period, but appeared cautious on future growth prospects. These near-term challenges notwithstanding, Facebook's status as a Technology powerhouse with an enviable future earnings potential remains unchanged. Driving this is the company’s huge user and advertiser base, higher engagement levels along with monetization opportunities presented by the Instagram, Oculus, Messenger and WhatsApp properties. (You can read the full research report on Facebook here.)

Other noteworthy reports we are featuring today include Baker Hughes , Eli Lilly (LLY - Free Report) and Fifth Third Bancorp (FITB - Free Report) .

Confidential: Best Trades from Zacks Research
Would you like to see a hand-picked "all-star" selection of investment ideas from the man who heads up Zacks' trading and investing services? Steve Reitmeister knows when key trades are about to be triggered and which of our experts has the hottest hand. He is now prepared to pass them along to you. Today Steve is also opening up Zacks' 7 Best Stocks for January, 2017 free of charge. From 220 Zacks Rank #1 Strong Buys, this Special tabs 7 for immediate breakout. Click to access these private picks>>

Mark Vickery

Senior Editor

Note: If you want an email notification each time Zacks Director of Research Sheraz Mian publishes a new article, please click here>>>


See More Zacks Research for These Tickers


Normally $25 each - click below to receive one report FREE:


Fifth Third Bancorp (FITB) - free report >>

Bristol Myers Squibb Company (BMY) - free report >>

Eli Lilly and Company (LLY) - free report >>

Published in